Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis (SIMCOMBIN)
Acquired channelopathies as contributors to development and progression of multiple sclerosis.
Simvastatin treatment does not protect retinal ganglion cells from degeneration in a rat model of autoimmune optic neuritis.
Delta-9-tetrahydrocannabinol + cannabidiol. A reasonable option for some patients with multiple sclerosis.
Neuromyelitis optica IgG does not alter aquaporin-4 water permeability, plasma membrane M1/M23 isoform content, or supramolecular assembly.
Neuroinflammatory Imaging Biomarkers: Relevance to Multiple Sclerosis and its Therapy.
Chronic pain following spinal cord injury.
Deimination restores inner retinal visual function in murine demyelinating disease.
Neuroscience. To learn is to myelinate.
Cell therapy for multiple sclerosis: an evolving concept with implications for other neurodegenerative diseases.
The MAO inhibitor phenelzine can improve functional outcomes in mice with established clinical signs in experimental autoimmune encephalomyelitis (EAE).
Progressive multifocal leukoencephalopathy: an unexpected complication of modern therapeutic monoclonal antibody therapies.
Vitamin D in health and disease: a literature review.
Acute Lymphoblastic Leukemia in a Man Treated With Fingolimod for Relapsing Multiple Sclerosis.
Preliminary analysis of month of birth in Iranian/Isfahan patients with multiple sclerosis.
Association between DPP6 polymorphism and the risk of progressive multiple sclerosis in Northern and Southern Europeans.
Brain-Derived Neurotrophic Factor in Neuroimmunology: Lessons Learned from Multiple Sclerosis Patients and Experimental Autoimmune Encephalomyelitis Models.
Perceived and actual arm performance in multiple sclerosis: relationship with clinical tests according to hand dominance.
Acute disseminated encephalomyelitis in Siriraj Hospital: clinical manifestations and short-term outcome.
Dementia in multiple sclerosis: Report of a case with cortical gray matter involvement and frontotemporal-like clinical features.
Transcriptional targeting of DCs with lentiviral vectors induces antigen-specific tolerance in a mouse model of multiple sclerosis.
Long-Term Neurocognitive, Psychosocial, and Magnetic Resonance Imaging Outcomes in Pediatric-Onset Acute Disseminated Encephalomyelitis.
A discrete-choice experiment to determine patient preferences for injectable multiple sclerosis treatments in Germany.
Copaiba Oil Suppresses Inflammatory Cytokines in Splenocytes of C57Bl/6 Mice Induced with Experimental Autoimmune Encephalomyelitis (EAE).
Prevalence and Significant Determinants of Post-traumatic Stress Disorder in a Large Sample of Patients with Multiple Sclerosis.
Pages
« first
‹ previous
…
261
262
263
264
265
266
267
268
269
…
next ›
last »